Vaclav Nemec
@vnemec.bsky.social
My expertise lies in the creative design of small molecules and synthetic strategies to tackle complex challenges in organic synthesis and medicinal chemistry and I thrive on the intellectual challenge of deconstructing complex problems in chemical biology
🧬 Life Science Spotlight 💊
TP53 is mutated in 37% of cancers, contributing to 46% of cancer deaths.Targeting p53 has been in the focus of cancer research for decades.
Researchers from Broad Institute, Harvard University and Dana-Farber came up with a new strategy:
www.linkedin.com/posts/v%C3%A...
TP53 is mutated in 37% of cancers, contributing to 46% of cancer deaths.Targeting p53 has been in the focus of cancer research for decades.
Researchers from Broad Institute, Harvard University and Dana-Farber came up with a new strategy:
www.linkedin.com/posts/v%C3%A...
November 20, 2025 at 2:53 PM
🧬 Life Science Spotlight 💊
TP53 is mutated in 37% of cancers, contributing to 46% of cancer deaths.Targeting p53 has been in the focus of cancer research for decades.
Researchers from Broad Institute, Harvard University and Dana-Farber came up with a new strategy:
www.linkedin.com/posts/v%C3%A...
TP53 is mutated in 37% of cancers, contributing to 46% of cancer deaths.Targeting p53 has been in the focus of cancer research for decades.
Researchers from Broad Institute, Harvard University and Dana-Farber came up with a new strategy:
www.linkedin.com/posts/v%C3%A...
🧬 Life Science Spotlight 💊
𝐅𝐢𝐧𝐚𝐥𝐥𝐲, 𝐂𝐫𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐎𝐧𝐜𝐨𝐠𝐞𝐧𝐢𝐜 𝐒𝐭𝐚𝐫 𝐏𝐥𝐚𝐲𝐞𝐫 𝐊𝐑𝐀𝐒
Teams of Alessio Ciulli, Kirsten McAulay and Peter Ettmayer, just reported ACBI4, a panKRAS degrader capable of targeting the main cancer-relevant KRAS variants.
For more, see my summary:
www.linkedin.com/posts/v%C3%A...
𝐅𝐢𝐧𝐚𝐥𝐥𝐲, 𝐂𝐫𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐎𝐧𝐜𝐨𝐠𝐞𝐧𝐢𝐜 𝐒𝐭𝐚𝐫 𝐏𝐥𝐚𝐲𝐞𝐫 𝐊𝐑𝐀𝐒
Teams of Alessio Ciulli, Kirsten McAulay and Peter Ettmayer, just reported ACBI4, a panKRAS degrader capable of targeting the main cancer-relevant KRAS variants.
For more, see my summary:
www.linkedin.com/posts/v%C3%A...
November 1, 2025 at 2:16 PM
🧬 Life Science Spotlight 💊
𝐅𝐢𝐧𝐚𝐥𝐥𝐲, 𝐂𝐫𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐎𝐧𝐜𝐨𝐠𝐞𝐧𝐢𝐜 𝐒𝐭𝐚𝐫 𝐏𝐥𝐚𝐲𝐞𝐫 𝐊𝐑𝐀𝐒
Teams of Alessio Ciulli, Kirsten McAulay and Peter Ettmayer, just reported ACBI4, a panKRAS degrader capable of targeting the main cancer-relevant KRAS variants.
For more, see my summary:
www.linkedin.com/posts/v%C3%A...
𝐅𝐢𝐧𝐚𝐥𝐥𝐲, 𝐂𝐫𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐎𝐧𝐜𝐨𝐠𝐞𝐧𝐢𝐜 𝐒𝐭𝐚𝐫 𝐏𝐥𝐚𝐲𝐞𝐫 𝐊𝐑𝐀𝐒
Teams of Alessio Ciulli, Kirsten McAulay and Peter Ettmayer, just reported ACBI4, a panKRAS degrader capable of targeting the main cancer-relevant KRAS variants.
For more, see my summary:
www.linkedin.com/posts/v%C3%A...
𝐒𝐦𝐚𝐫𝐭 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐨𝐰𝐞𝐫𝐡𝐨𝐮𝐬𝐞 🎯
By creating enzyme-responsive nanoparticles that self-assemble in tumors and chemically "click" with an arsenic payload, scientists achieved complete tumor eradication and durable immune memory.
www.linkedin.com/posts/v%C3%A...
By creating enzyme-responsive nanoparticles that self-assemble in tumors and chemically "click" with an arsenic payload, scientists achieved complete tumor eradication and durable immune memory.
www.linkedin.com/posts/v%C3%A...
October 15, 2025 at 7:48 AM
𝐒𝐦𝐚𝐫𝐭 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐨𝐰𝐞𝐫𝐡𝐨𝐮𝐬𝐞 🎯
By creating enzyme-responsive nanoparticles that self-assemble in tumors and chemically "click" with an arsenic payload, scientists achieved complete tumor eradication and durable immune memory.
www.linkedin.com/posts/v%C3%A...
By creating enzyme-responsive nanoparticles that self-assemble in tumors and chemically "click" with an arsenic payload, scientists achieved complete tumor eradication and durable immune memory.
www.linkedin.com/posts/v%C3%A...